Hematuria Articles

Patients with metastatic and locally advanced bladder or prostate cancer may suffer from pelvic symptoms such as pain, obstruction, and hemorrhage. Local tumor growth is associated with significant morbidity and systemic therapy is often ineffective.

ORLANDO, FL USA (UroToday.com) - Hematuria is associated with renal cell carcinoma (RCC). However, its relationship with specific pathologic subtypes has not been evaluated. Michael Hanzly and colleagues sought to evaluate whether hematuria could be predictive for subtype of RCC and benign renal masses.

Strategies to ensure timely diagnostic evaluation of hematuria are needed to reduce delays in bladder cancer diagnosis.

To evaluate the performance of electronic trigger algorithms to detect delays in hematuria follow-up.

SAN DIEGO, CA USA (UroToday.com) - Dr. Khurshid Ghani and colleagues presented the first analysis of the incidence and costs of imaging for hematuria in the emergency department (ED) setting using the Nationwide Emergency Department Sample (NEDS) data (U.S. population-based cohort) to determine the prevalence, costs and predictors of imaging utilization in patients who presented to ED with hematuria between 1/1/2006 and 12/31/2009.

Bladder cancer has a high incidence and involves high associated morbidity and mortality. Since its initial clinical suspicion, early diagnostic confirmation and multimodal treatment involve different medical specialties.

Computed tomography urogram (CTU) is recommended when investigating patients with hematuria. We determine the incidence of urinary tract cancer and compare the diagnostic accuracy of CTU and renal and bladder ultrasound (RBUS) at identifying urinary tract cancer.

BERKELEY, CA (UroToday.com) - Natural clustering of hematuria patients according to their biomarker profiles

To determine the cumulative incidence of overall and severe radiation cystitis in a high volume cohort of patients and to investigate its potential predictive factors.

We have performed a retrospective analysis of clinical data from patients diagnosed with localized prostate cancer and treated with radiotherapy at our institution (June 2005-January 2013), and quantified the cumulative incidence of radiation cystitis.

To quantify and examine the aetiology of delays in the diagnosis and initial treatment of patients with bladder cancer in Western Australia.

All attendances at a one-stop haematuria clinic at a public tertiary-level hospital in Western Australia between May 2008 and April 2014 were reviewed retrospectively.

The present study sought to identify a panel of DNA markers for noninvasive diagnosis using cell-free DNA (cfDNA) from urine supernatant or cellular DNA from urine sediments of hematuria patients. A panel of 48 bladder cancer-specific genes was selected.

Despite suboptimal sensitivity, urine cytology is often performed as an adjunct to cystoscopy for bladder cancer diagnosis. We aimed to develop a non-invasive, fast molecular diagnostic test for bladder cancer detection with better sensitivity than urine cytology while maintaining adequate specificity.

To gain new insights into the origin and prevention of diagnostic delays in the evaluation of hematuria in an electronic health record (EHR)-based integrated care setting.

We performed a retrospective review of 298 consecutive patients with new-onset hematuria at a Veterans Affairs facility from January 1, 2011 to December 31, 2013 excluding those where diagnostic evaluation was unnecessary (i.

Urinary cell-free DNA (ucfDNA) has great potential as a "liquid biopsy" for use in diagnosis of urological cancers. In this study, we compared ucfDNA gene expression levels between patients with bladder cancer (BC) and those with hematuria, and determined whether they could be used as a noninvasive urine-based marker.

Many patients enter the care cycle with gross or microscopic hematuria and undergo a cystoscopy to rule out bladder cancer. Sensitivity of this invasive examination is limited, leaving many patients at risk of having undetected cancer.

To develop technical guidelines for magnetic resonance imaging aimed at characterising renal masses (multiparametric magnetic resonance imaging, mpMRI) and at imaging the bladder and upper urinary tract (magnetic resonance urography, MRU).

Although many treatments have been applied to treat hormone-refractory prostate cancer (HRPC), therapeutic outcome is not altogether satisfactory.

Bladder cancer is the fourth most common cancer in men, and is associated with significant morbidity and mortality. Pathologic evaluation of urothelial cancers relies predominantly on histomorphologic features but can be aided in a small subset of cases by immunohistochemical analyses.

MDCTU is a preferred method for the investigation of malignant lesions in the upper urinary tract. However, to decrease unnecessary radiation exposure the indications for the exam in different groups of patients should be assessed.

The occurrence of primary carcinoma of the ureteral stump following radical nephrectomy for renal cell carcinoma is extremely rare; 7 patients with the disease have been reported previously. All these patients were males with transitional cell carcinoma.

Small cell carcinoma of the urinary bladder (SCCB) is an extremely rare but aggressive tumour constituting less than 0.7% of all urinary bladder tumours. It is often misdiagnosed as transitional cell carcinoma, owing to the similarities in presentation.

We present the radiologic findings in a case of prostate brachytherapy seed migration to the bladder presenting as gross hematuria. While prostate brachytherapy seed implantation is considered a relatively safe procedure, migration is not uncommon; however, it is usually clinically silent and the seeds most commonly migrate to the lungs through the venous circulation via the periprostatic venous plexus.

To present outcomes for prostatic artery embolization (PAE) to treat urinary retention and gross prostatic hematuria in non-index benign prostatic hyperplasia (BPH) patients.

and Methods: 75 patients undergoing PAE from December 2013 through August 2018 (age=77.

To understand urethral secondary malignancies among patients treated with brachytherapy (BRT) for primary prostate cancer.

Institutional retrospective review identified 13 patients evaluated from 2003-2014 with urethral cancer and prior history of BRT monotherapy for prostate cancer.

MIAMI, FL USA (UroToday.com) - This was a retrospective review of all men (n=25) who had >1 cystoscopy at a single institution, by 2 experienced urologists, between 2002 and 2014, and had ≥ 3 month follow-up. The determination of urethral stricture was according to the Purohit-Blaivas staging system. Exclusion criteria were men who were performing intermittent catheterization and those that had intervention between cystoscopies.

To investigate the symptoms and delays in the clinical pathway of bladder cancer (BC).

This is a substudy of a prospective, randomized, multicenter phase III study (FinnBladder 9, NCT01675219) where the efficacy of photodynamic diagnosis and 6 weekly optimized mitomycin C instillations are studied in pTa bladder cancer with high risk for recurrence.

This paper is to elucidate the correlation between different symptoms of UTUC and the clinicopathological characteristics and prognosis. The clinicopathological data of 700 consecutive patients with UTUC who were treated with radical nephroureterectomy were reviewed, and symptoms were categorized into three groups: S1-no direct symptoms, S2-local symptoms (including hematuria and flank pain) and S3-systemic symptoms.

To evaluate the effects of short term use of finasteride and dutasteride on amount of intraoperative blood loss and microvessel density (MVD) of prostatic stromal and suburethral tissues in patients with benign prostatic hyperplasia (BPH) prior to TURP METHODS: The study involved 450 male patients who planned to have TURP and were prospectively randomised into three groups (150 patients each).

The most common symptom of bladder cancer (BC) is hematuria. However, not all patients with hematuria are diagnosed with BC. Here, we explored a novel method to discriminate BC from hematuria under non-malignant conditions by measuring differences in urinary cell-free microRNA (miRNA) expression between patients with BC and those with hematuria.

Early diagnosis of bladder cancer is crucial for improvement of cancer specific survival and recurrence rate. We analyzed the possible role of fluorescence urine analysis in bladder cancer diagnosis.

To better characterize the urinary microbiome in males and contribute to overall understanding of the urinary microbiota specifically in patients undergoing evaluation for possible bladder cancer, stratified by risk exposure to smoking.

Urinary tract cancers are common and comprise a gamut of lesions ranging from small benign tumors to aggressive neoplasms with high mortality. The predominant urinary tract malignancy is bladder cancer.

To determine the time to bladder cancer diagnosis from initial infection-like symptoms and its impact on cancer outcomes.

Using Surveillance, Epidemiology and End Results-Medicare, we designed a retrospective cohort study identifying beneficiaries aged ≥66 years diagnosed with bladder cancer from 2007 to 2009.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is associated with significant manipulation of the urinary tract (UT). We aim to describe the urological events and their management in patients who underwent CRS-HIPEC.

To report a series of 5 patients with urothelial bladder cancer (UBC) three of them with a history of exposure to amines and only two with gross hematuria.

After obtaining ethical and legal authorization, we performed a restrospective monocentric study.

Bladder urothelial papilloma is extremely rare in the paediatric population. It usually presents as painless gross haematuria and its diagnosis implies a high index of suspicion as other causes of haematuria predominate in this age range.

Only 3-28% of patients referred to the urology clinic for hematuria are diagnosed with bladder cancer (BC). Cystoscopies lead to high diagnostic costs and patient burden. Therefore, to improve selection of patients for cystoscopy, reduce costs and over-testing we aimed to validate a recently developed diagnostic urine assay MATERIALS AND METHODS: We included 200 patients from three European countries undergoing cystoscopy for hematuria (n=97 BC, n=103 non-malignant).

To evaluate the utility of virtual cystoscopy (VC) performed with CT urography in patients being studied under gross hematuria or patients being followed-up after a previous bladder cancer and compare the results with those obtained with gold standard technique (optical cystoscopy).